Clinical Trials /

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

NCT02532010

Description:

The purpose of this study is to see if a medicine called pacritinib is both safe and effective as a study intervention for patients with AML in combination with either decitabine or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute myeloid leukemia (AML). Decitabine and cytarabine are both FDA approved drugs that are used in treatment of AML. Pacritinib is being tested in clinical trials and has not been submitted to the U.S. Food and Drug Administration (FDA) for approval for any indications. Pacritinib is a drug that is designed to slow down the growth of leukemic cells.

Related Conditions:
  • Acute Myeloid Leukemia
Recruiting Status:

Terminated

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
  • Official Title: Induction Therapy With Pacritinib Combined With Decitabine or Cytarabine in Older Patients With Acute Myeloid Leukemia (AML)

Clinical Trial IDs

  • ORG STUDY ID: 1403014921
  • NCT ID: NCT02532010

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DrugSynonymsArms
PacritinibSB1518Arm A: Pacritinib and Decitabine
DecitabineDacogenArm A: Pacritinib and Decitabine
CytarabineCytosar-U, Tarabine PFS, CytosarArm B: Pacritinib and Cytarabine

Purpose

The purpose of this study is to see if a medicine called pacritinib is both safe and effective as a study intervention for patients with AML in combination with either decitabine or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute myeloid leukemia (AML). Decitabine and cytarabine are both FDA approved drugs that are used in treatment of AML. Pacritinib is being tested in clinical trials and has not been submitted to the U.S. Food and Drug Administration (FDA) for approval for any indications. Pacritinib is a drug that is designed to slow down the growth of leukemic cells.

Detailed Description

      This is a single-center, open label, two-arm phase II study of clinical activity of
      pacritinib in older patients newly diagnosed with AML combined with either decitabine or
      cytarabine. In this study, approximately 61 patients will be enrolled at the Weill Cornell
      Medical College. Arm A consists of pacritinib and decitabine and will enroll 31 subjects, and
      Arm B consists of pacritinib and cytarabine and will enroll 30 subjects. Arm A and B will
      enroll sequentially. The dose of pacritinib will be 200mg twice a day continuously.

      Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing
      pacritinib 200 mg twice daily.

      Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing
      pacritinib 200mg twice daily.

      Treatment may be given on an outpatient basis if hospitalization is not otherwise required.
      Every effort should be made to give decitabine or cytarabine consecutively for 10 days;
      however if interruption is needed, discussion will be held with the medical monitor and the
      investigator.

      The first day of a cycle will be defined as the day on which decitabine or cytarabine is
      started. First treatment will take place on Cycle 1, day 1. Hydroxyurea may be used at the
      investigator's discretion for the first 28 days on Cycle 1 to maintain white blood cell count
      (WBC) <30,000/µl. Bone marrow biopsy and aspiration will be performed between days 22-56 of
      each cycle and the subsequent treatment cycle will be started between days 22-56, at the
      investigator's discretion. Ideally, cycles will be administered at 28-day intervals, but
      treatment delays of decitabine or cytarabine up to 56 days will be permitted to allow
      resolution of non-hematologic and non-disease-related hematologic toxicities.
      Granulocyte-stimulating cytokine support will be permitted at the investigator's discretion
      in the event of neutropenic fever/sepsis as per American Society of Clinical Oncology (ASCO)
      guidelines.16 Bone marrow aspiration and biopsy will be performed within 5 days of peripheral
      blood count recovery to an absolute neutrophil count (ANC) ≥ 1000/µL and platelets ≥
      100,000/µL without transfusions, or day 28 whichever comes first. If the peripheral blood
      absolute blast count is ≥ 5000/µL on day 21 of the first cycle, the second cycle may be
      administered immediately after bone marrow aspiration and biopsy.

      Each arm will enroll in a Simon's two-stage design as described in Section 8. In Arm A, 16
      subjects will initially be entered into the study, and if 6 or fewer respond, then Arm A will
      be terminated early and study will proceed to Arm B. In Arm B, 15 subjects will initially be
      entered into the study, and if 2 or fewer respond, the study will be terminated early.

      Duration of study therapy Patients will receive a minimum of 4 cycles of treatment unless
      there is evidence of unacceptable regimen-related toxicity or unequivocal disease progression
      for which the investigator is specifically recommending alternative therapy. Pacritinib will
      continue throughout the study.

      Arm A:

      Patients who achieve Complete Remission (CR), Complete Remission with incomplete platelet
      recovery (CRp), or complete remission with incomplete blood count recovery (CRi) will receive
      subsequent cycles of decitabine on a monthly basis with decitabine 20mg/m2 IV daily for 5
      days with pacritinib. Patients who do not achieve complete remission, but who are responding
      to treatment (partial response, hematologic response, or clinical benefit as determined by
      the investigator) will receive four 10-day cycles of decitabine with pacritinib as indicated
      in the study design, followed by monthly maintenance cycles of decitabine 20mg/m2 IV daily
      for 5 days + daily pacritinib. The maintenance cycles will continue indefinitely until
      relapse or toxicity. Patients may be taken off study for allogeneic stem cell transplantation
      at the discretion of the investigator.

      Arm B:

      Patients will continue cytarabine 20mg subcutaneous twice daily for 10 days combined with
      pacritinib for up to 4 cycles to achieve CR, CRp, or CRi. Those patients who achieve CR, CRp,
      or CRi after 4 cycles may continue to receive monthly maintenance of cytarabine 20mg
      subcutaneous twice daily for 10 days with pacritinib. The maintenance cycles will continue
      indefinitely until relapse or toxicity. Patients may be taken off study for allogeneic stem
      cell transplantation at the discretion of the investigator.

      Screening (Study Day -14 to Day 1) Initiate and complete screening activities within 14 days
      before Cycle 1, Day 1 treatment.

      Treatment (Cycle 1, Day 1 through End-of-Treatment Visit) This period begins on the day the
      patient first receives treatment and ends at the End-of-Treatment Visit.

      Follow-up After completion of the End-of-Treatment Visit, all patients are followed up for 30
      days and followed every three months for survival and disease status.

      Clinical Study Endpoints The Primary objective of the study is to evaluate the safety and
      efficacy of pacritinib combined with decitabine or cytarabine in newly diagnosed older (≥65
      years old) patients with AML. The primary endpoint of this study will be complete remission
      according to the International Working Group (IWG) criteria.

      The following secondary endpoints will be evaluated:

        -  Overall Survival (OS)

        -  Overall remission (OS) rate, defined as CR + CRp + Cri + Partial Remission (PR) based on
           IWG response criteria

        -  Relapse-free Survival (RFS)

        -  Event-free Survival (EFS)

        -  Time to Complete Response (TTCR)

        -  Remission Duration

      DISCUSSION OF STUDY DESIGN

      Prognosis for older patients with AML is poor, with median survival of only 9-12 months.
      Older patients are often not candidates for intensive chemotherapy or allogeneic stem cell
      transplantation. Decitabine and low-dose cytarabine are frequently used for upfront treatment
      of older AML patients, however CR rates are 40-50% with decitabine and 18% with cytarabine.
      Pacritinib is a potent tyrosine kinase inhibitor of FLT3 and Janus Kinase 3 (JAK3) tyrosine
      kinases. The objective of the proposed clinical trial is to evaluate the efficacy, safety,
      and feasibility of pacritinib combined with decitabine or cytarabine in newly diagnosed older
      AML patients. The primary endpoint will be increase in complete remission.
    

Trial Arms

NameTypeDescriptionInterventions
Arm A: Pacritinib and DecitabineActive ComparatorArm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
  • Pacritinib
  • Decitabine
Arm B: Pacritinib and CytarabineActive ComparatorArm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
  • Pacritinib
  • Cytarabine

Eligibility Criteria

        Inclusion Criteria:

          1. Patient has unequivocal pathologic diagnosis of AML (≥ 20% blasts in the bone marrow
             based on World Health Organization (WHO) criteria), excluding acute promyelocytic
             leukemia t(15;17)(q22;q12); Promyelocytic leukemia gene (PML)- retinoic acid receptor
             alpha (RARA)

          2. Age ≥ 65 years old

          3. No prior treatment for AML except:

               -  Emergency leukapheresis

               -  Emergency treatment for hyperleukocytosis with hydroxyurea

               -  Cranial radiotherapy (RT) for Central Nervous System (CNS) leukostasis (one dose
                  only)

               -  Growth factor/cytokine support

          4. AML patients with therapy-related myeloid neoplasms are eligible if they have not
             received radiation therapy or chemotherapy (not including hormonal therapy) for their
             primary malignancy or disorder for ≥ 6 months. Hydroxyurea may be used at the
             investigator's discretion up to the first 28 days on Cycle 1 to maintain WBC
             <30,000/µl.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          6. Subjects must have adequate hepatic and renal function

          7. Female subject of child-bearing potential and male subjects with female partners of
             reproductive potential must use acceptable contraceptive methods

          8. Able to understand and to provide written informed consent

          9. Able to comply with all study procedures during the study including all visits and
             tests

         10. Willing to adhere to the prohibitions and restrictions specified in this protocol

         11. Patient must sign an informed consent form (ICF)

        Exclusion Criteria:

          1. Prior treatment with decitabine

          2. Prior treatment with cytarabine

          3. Prior treatment with pacritinib

          4. Presence of serious illness, medical condition, or other medical history, involving
             the heart, kidney, liver, or other organ system, including abnormal laboratory
             parameters, which, in the opinion of the Investigator, would be likely to interfere
             with a subject's participation in the study or with the interpretation of the results.

          5. Active, uncontrolled, clinically significant infection(s)

          6. Have other active malignancies (excluding other myeloid hematologic malignancies) or
             other malignancies within 12 months before enrollment, except curatively treated
             non-melanoma skin cancer, cervical intraepithelial neoplasia, organ-confined or
             treated non-metastatic prostate cancer with negative prostate-specific antigen, in
             situ breast carcinoma after complete surgical resection, or superficial transitional
             cell bladder carcinoma

          7. Are receiving any other investigational therapy or protocol-prohibited therapy

          8. Any prior or co-existing medical condition that in the Investigator's judgment will
             substantially increase the risk associated with the subject's participation in the
             study

          9. Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary study procedures

         10. Any gastrointestinal (GI) or metabolic condition that could interfere with absorption
             of oral medication

         11. Inflammatory or chronic functional bowel disorder, such as Crohn's disease,
             inflammatory bowel disease, chronic diarrhea

         12. Clinically symptomatic and uncontrolled cardiovascular disease

         13. History of any of the following within 6 months: myocardial infarction,
             severe/unstable angina, or symptomatic congestive heart failure

         14. New York Heart Association Class III or IV congestive heart failure

         15. Patients with National Cancer Institute (NCI) Common Terminology for Adverse Events
             (CTCAE) grade 2 cardiac arrhythmias may be considered for inclusion with the approval
             of the investigator if the arrhythmias are stable, asymptomatic and unlikely to affect
             patient safety. Patients will be excluded if they have ongoing cardiac dysrhythmias of
             CTCAE grade 3, corrected QT interval (QTc) prolongation >450 ms by Fridericia method,
             or other factors that increase the risk for QT prolongation (eg, heart failure,
             hypokalemia [defined as serum potassium < 3.0 milliequivalent (mEq/L) that is
             persistent and refractory to correction], or family history of long QT interval
             syndrome).
      
Maximum Eligible Age:N/A
Minimum Eligible Age:65 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Complete Remission Rate
Time Frame:6 months
Safety Issue:
Description:Complete remission rate is defined as number of subjects with complete remission according to the IWG criteria, which is defined by presence of <5 percent of blasts in the bone marrow, absence of blasts with Auer rods, absence of extramedullary disease, absolute neutrophil count >1.0 x 109/L (1000/µL); platelet count >100 x 109/L (100,000/µL); independence of red cell transfusions.

Secondary Outcome Measures

Measure:Overall Survival
Time Frame:2 years
Safety Issue:
Description:Survival following treatment to the date of death
Measure:Overall Remission Rate
Time Frame:6 months
Safety Issue:
Description:Overall remission rate is defined as number of subjects with complete remission (CR), Complete Remission with incomplete platelet recovery (CRp), Complete Remission with Incomplete Blood Count Recovery (CRi), Partial Remission (PR) according to the IWG criteria. CRi is defined as All CR criteria except for residual neutropenia (<1.0 x 109/L (1000/µL)) or thrombocytopenia (<100 x 109/L (100,000/µL)), PR is defined as relevant in the setting of phase I and II clinical trials only; all hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pretreatment bone marrow blast percentage by at least 50 percent.
Measure:Relapse-free Survival
Time Frame:From date of complete remission until either AML relapse or death from any cause, whichever came first, assessed throughout the study period up to 2 years
Safety Issue:
Description:Time from complete remission documentation to either AML relapse or death from any cause.
Measure:Event-free Survival
Time Frame:Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause, assessed throughout the study period up to 2 years
Safety Issue:
Description:Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause
Measure:Time to Complete Response
Time Frame:From entry on study until complete remission, assessed throughout the study period up to 2 years
Safety Issue:
Description:Time from entry on study until documentation of complete remission (CR)
Measure:Remission Duration
Time Frame:time from complete remission to AML relapse, assessed throughout the study period up to 2 years.
Safety Issue:
Description:Time from CR documentation to AML relapse

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Weill Medical College of Cornell University

Last Updated